Related Experiment Video
Updated: Jun 26, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
Hyperglycemia in Cancer Patients.
Anil Bhoraskar1, Mubarkunnisa Tonse2, Suhas Agre2
1Senior Diabetologist, Department of Diabetology and Endocrinology, Chumbal Hill Hospital, Asian Cancer Institute, Mumbai, Maharashtra, India, Corresponding Author.
Summary
Hyperglycemia in cancer patients complicates treatment and worsens outcomes. Prompt diagnosis and management of high blood sugar are crucial for better cancer care and survival.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Cancer patients frequently have comorbid conditions like diabetes mellitus and hypertension.
- Hyperglycemia, occurring before, during, or after cancer therapy, is linked to adverse outcomes, including treatment compromise and increased mortality.
- Effective management of comorbid conditions is integral to a multidisciplinary cancer treatment approach.
Purpose of the Study:
- To highlight the association between cancer-directed therapies and hyperglycemia.
- To inform healthcare providers about medications that can induce or exacerbate hyperglycemia in cancer patients.
- To emphasize the importance of timely hyperglycemia diagnosis and management during cancer treatment.
Main Methods:
- Literature review of studies investigating hyperglycemia in cancer patients.
- Analysis of cancer treatment modalities and their impact on glucose metabolism.
- Identification of specific cancer therapies linked to hyperglycemia.
Main Results:
- Various cancer-directed therapies are associated with the development or worsening of hyperglycemia.
- Understanding these associations is critical for anticipating and managing glucose dysregulation.
- Proactive monitoring and intervention are necessary to mitigate negative impacts.
Conclusions:
- Hyperglycemia is a significant concern in cancer care, affecting treatment efficacy and patient survival.
- Oncology and primary care providers must be vigilant regarding hyperglycemia risks associated with cancer therapies.
- Integrated management strategies are essential for optimizing outcomes in cancer patients with hyperglycemia.
More Related Videos
Related Concept Videos
01:15Hypoglycemia and Glucagon
257
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
257
01:15Diabetes: Symptoms, Diagnosis, and Complications
526
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
526
01:22Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
192
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192
02:53Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
01:19Psychoneuroimmunology: Diabetes and Cancer
28
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
28